Melatonin for Perimenopause: More Than a Sleep Aid

The pineal gland's melatonin production declines naturally with age — women in their late 40s and 50s produce roughly 50% less melatonin than they did at 20. Estrogen modulates the sensitivity of the pineal gland and the expression of melatonin synthesis enzymes (particularly HIOMT); estrogen decline accelerates the age-related fall in melatonin production. Hot flashes occurring at night — which involve vasodilation and autonomic arousal — suppress melatonin release by activating the same sympathetic pathways that morning light uses to inhibit melatonin. The result is delayed sleep onset (insufficient melatonin rise at bedtime), disrupted sleep architecture, and a blunted circadian signal that impairs daytime alertness and mood.

Melatonin is one of the body's most potent antioxidants — it scavenges hydroxyl radicals, superoxide anions, and hydrogen peroxide, protecting neurons from the oxidative stress that accelerates as estrogen's antioxidant protection declines. Neuronal mitochondria are particularly rich in melatonin receptors (MT1 and MT2), and melatonin supports mitochondrial function by reducing electron leakage from the transport chain. Studies show melatonin reduces amyloid-beta aggregation and tau hyperphosphorylation — the hallmarks of Alzheimer's pathology — in animal models, with epidemiological data suggesting higher melatonin is associated with lower dementia risk. This positions melatonin supplementation as a neuroprotective strategy during the perimenopausal window when Alzheimer's risk trajectory diverges between men and women.

Less is more with melatonin: physiological doses (0.3–1mg) taken 60–90 minutes before target bedtime are more effective than the high doses (5–10mg) common in commercial products, which overwhelm melatonin receptors and can cause grogginess and receptor downregulation. The timing — not just the dose — is critical: melatonin taken at the right phase of the circadian cycle (1–2 hours before natural sleep onset) effectively shifts the circadian clock; taken at the wrong time, it is far less effective. Extended-release formulations (targeting middle-of-night awakenings) may be preferable for perimenopausal women whose primary problem is sleep maintenance rather than sleep onset. Melatonin pairs well with magnesium glycinate, glycine, and L-theanine for comprehensive sleep architecture support.